At a family wedding earlier this month, an uncle was salivating over the prospect that the Vivus Inc. drug Qnexa could soon become the first in a new generation of obesity drugs to gain FDA approval. He needed to lose…
Category Archives: Drug Approval
What Drug Problem?
May 17, 2012 – 2:44 pm
Pop quiz . . . which market is valued higher, illegal drugs or prescription drugs?
He Said What?!?! Best Biotech Quotes of 2011
December 29, 2011 – 3:26 pm
As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…
World’s Oldest Clinical Trial . . . and Health Economics Not Far Behind
November 4, 2011 – 11:18 am
How old is our clinical trial system?
Reason Free from Passion? That’s Not Biotech
October 27, 2011 – 9:24 am
SAN FRANCISCO ‑ At this week’s BIO Investor Forum in San Francisco, there was talk of how the biotech industry has squandered money, paying for infrastructure when it should have been paying only for development and continuing to fund programs…
Pfizer’s Greg Simon Talks Change Blindness in Drug Development
October 20, 2011 – 12:04 pm
If you walked up to a desk to sign a consent form for an experiment, and the person behind the desk bent down to file your form, and a different person stood up – someone with a clearly different face,…
Unless it’s Affordable, Curing Cancer is Just a Dream
August 30, 2011 – 12:43 pm
Although they’re the stuff of science, statistics too often lack the power to move us. After all, they’re just numbers. So when companies like Dendreon Corp. and Seattle Genetics Inc. price their cancer treatments at nearly $100,000 or more, we…
Don’t Price Drugs on What the Market Used to Bear
August 9, 2011 – 9:52 am
All those warnings about price pressures and reimbursement woes – they didn’t come from Chicken Little. The sky really could be falling for drugmakers that insist on pricing their products based on what the market used to bear.
Video Coverage from #BIO2011 – Exclusive Interview with AVANIR Pharmaceuticals
June 29, 2011 – 5:25 pm
Today at the 2011 Bio International Convention, we had the opportunity to speak with Keith A. Katkin, President and Chief Executive Officer of Avanir Pharmaceuticals. Katkin discusses the recent FDA approval of Nuedexta for the treatment of pseudobulbar affect (PBA).
Join the Conversation